Evaxion Biotech A/S held its Annual General Meeting on April 16, 2024, where significant decisions included the approval of an annual report, the transfer of a loss to the next financial year, and the authorization to issue warrants totaling up to DKK 100 million. Shareholders approved increasing share capital by DKK 80 million and re-elected board members, including Kathleen Thordal. At the meeting, 14,362,031 ordinary shares, or 27.5% of total shares, were voted.